HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Syncom Formulations India Ltd Stock Comparison

Alivus Life Sciences Ltd vs Syncom Formulations India Ltd Stock Comparison

Last Updated on: Aug 06, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 948.35 as of 06 Aug 10:47.
  • The P/E Ratio of Alivus Life Sciences Ltd is 0 as of March 2022 .The P/E Ratio of Syncom Formulations (India) Ltd is 46.2 as of March 2022.
  • The Market Cap of Alivus Life Sciences Ltd is ₹ 0 crore as of March 2022 .The Market Cap of Syncom Formulations (India) Ltd is ₹ 916.79 crore as of March 2022.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 155.83 crore as compare to the Dec '24 revenue of ₹ 131.57 crore. This represent the growth of 18.44%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Syncom Formulations (India) Ltd for the Mar '25 is ₹ 24.7 crore as compare to the Dec '24 ebitda of ₹ 18.77 crore. This represent the growth of 31.59%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Syncom Formulations (India) Ltd changed from ₹ 4.4 crore to ₹ 17.69 crore over 8 quarters. This represents a CAGR of 100.51% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Syncom Formulations (India) Ltd changed from 13.07 % on March 2022 to 0 % on March 2024 . This represents a CAGR of -100.00% over 3 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
  • The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Syncom Formulations (India) Ltd

  • Incorporated as a private limited Company in 1988, Syncom Formulations (India) Limited was converted into a public limited Company in June, 1992.
  • The Company in the Indian Pharmaceutical Industry represents synergistic combination of commitment and consistency.
  • Syncom possesses the manufacturing strength in its own manufacturing set-up at Pithampur, Madhya Pradesh. Established in 1988, Syncom plant is geared up with latest production machineries and maintains high quality standards.
  • Currently, the Company manufactures and markets more than 200 pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. The company set up a manufacturing facility at Palghar, Thane to produce pharmaceutical formulations.

Alivus Life Sciences Ltd News Hub

News

Alivus Life Sciences to declare Quarterly Results

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 1 Aug...

Read more

25 Jul 2025 11:06

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

Syncom Formulations (India) Ltd News Hub

News

Syncom Formulations (India) to table results

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

04 Aug 2025 11:23

News

Syncom Formulations (India) schedules board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

14 May 2025 14:06

News

Syncom Formulations (India) to convene board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company o...

Read more

05 Nov 2024 14:12

News

Syncom Formulations (India) schedules AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 17:48

News

Syncom Formulations (India) to hold AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company...

Read more

20 Sep 2024 10:30

News

Syncom Formulations gains after Q1 PAT rises over 73% YoY

Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total e...

Read more

13 Aug 2024 13:37

SWOT Analysis Of Syncom Formulations (India) Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

BlinkX Score for Syncom Formulations (India) Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Syncom Formulations (India) Ltd?

Market cap of Alivus Life Sciences Ltd is 12,108 Cr while Market cap of Syncom Formulations (India) Ltd is 1,707 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd?

The stock performance of Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd?

As of August 6, 2025, the Alivus Life Sciences Ltd stock price is INR ₹987.4. On the other hand, Syncom Formulations (India) Ltd stock price is INR ₹18.17.

How do dividend payouts of Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Syncom Formulations (India) Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions